Overview

Oral AMXT 1501 Dicaprate in Combination With IV DFMO

Status:
Recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
A Phase 1B/2A study will be conducted to establish safety and dose level of AMXT 1501 dicaprate in combination with IV DFMO, in cancer patients.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Aminex Therapeutics, Inc.
Treatments:
Eflornithine